Clinical trials: 5-FU
Colorectal Cancer
Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)
Surgery is the main treatment method for colon cancer. About 50% of patients can be cured with surgery alone. For colon cancer with high-risk stage II or III after surgery, the current guidelines recommend 3-6 months after…
- Trial name
- AFFORD (NCT05427669)
- Testing
- mFOLFOXIRI, mFOLFOX6
- Volunteers
- 340 people
- Sponsor
- Yanhong Deng
Vaginal Atrophy
Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments
The CO2RE laser system is a fractional CO2 laser that is FDA approved under a 510(k) K101321 for dermatologic procedures requiring ablation and coagulation of soft tissues, including the skin Eligible subjects will undergo 3…
- Trial name
- NCT02704741
- Testing
- CO2RE
- Where
- 4 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Syneron Medical
Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy
Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC
This is a two-arm, randomized phase II clinical study. It is planned to enroll 44 patients with primary left-sided, RAS and BRAF wild-type metastatic colorectal cancer.
- Trial name
- NCT07070713
- Testing
- FOLFOXIRI + QL1706 + Bevacizumab, FOLFOX+QL1706+Cetuximab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fujian Cancer Hospital
Stomach Neoplasms, Esophageal Neoplasms
Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer
This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for gastric cancer.
- Trial name
- NCT00042510
- Testing
- Treatment group
- Volunteers
- 103 people
- Sponsor
- Cancer Advances Inc.
HER2-negative Breast Cancer, Advanced Breast Cancer
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
This is a phase II, multicenter, open-label, randomized controlled trial to compare the efficacy of organoid-guided treatment (OGT) to treatment of physician's choice (TPC) in previously treated, HER2-negative locally advanced or…
- Trial name
- ORIENTA (NCT06102824)
- Testing
- Organoid-guided treatment, Taxane, Capecitabine
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Guangdong Provincial People's Hospital
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
The purpose of this study is to evaluate the safety, tolerability and maximum tolerated dose of tislelizumab in combination with pamiparib plus chemoradiotherapy (chemotherapy and radiation) in individuals with recurrent head and…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV
- Trial name
- NCT05526924
- Testing
- Chemoradiation, Pamiparib, Hydroxyurea
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Advanced Malignant Tumors
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced malignant tumors
- Trial name
- NCT05229497
- Testing
- AK112, AK117, Carboplatin
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Akeso
Stage IV Colorectal Cancer, Gastric Cancer
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
The purpose of this study is to investigate the association between UGT1A1 polymorphisms and neutropenia and diarrhea in Korean patients with advanced colorectal or gastric cancer treated with FOLFIRI regimen.
- Trial name
- NCT01271582
- Testing
- Irinotecan, 5FU, leucovorin
- Where
- 5 sites in South Korea
- Volunteers
- 1,500 people
- Sponsor
- Asan Medical Center
HPV-Related Squamous Cell Carcinoma, HNSCC
Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
Carboplatin, nab-paclitaxel, and nivolumab combination will be administered for three cycles of three weeks duration each. TORS or RT/CRT will be performed after induction chemotherapy (i.e. day 64 of therapy).
- Trial name
- OPTIMA-II (NCT03107182)
- Testing
- nab-paclitaxel, Carboplatin, Nivolumab
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Chicago
Locally Advanced Rectal Cancer
Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.
The Efficacy and Safety of Long-Course Preoperative Chemoradiotherapy Combined with Consolidation or Induction NALIRIFOX Chemotherapy in the Treatment of Locally Advanced Rectal Cancer: A Prospective, Multicenter, Phase II Study.
- Trial name
- NCT06894797
- Testing
- Concurrent Chemoradiotherapy（Radiation + Capecitabine）, irinotecan hydrochloride liposome injection, Oxaliplatin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Peking University Cancer Hospital & Institute
Anal Canal Cancer
Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer
The purpose of this study is to see whether avoiding preventative radiation to the groin in patients with normal sentinel node biopsy and PET-CT, is at least as effective treating cancer as giving preventative radiation to the…
- Trial name
- INSPIRE (NCT05040815)
- Testing
- chemo-radiation treatment
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- AHS Cancer Control Alberta
Locally Advanced Rectal Carcinoma
Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer
The goal of this clinical trial is to test the efficacy and safety in patients with locally advanced middle and lower rectal cancer.
- Trial name
- NeoCaCRT (NCT05792735)
- Testing
- Cadonilimab Injection, Short-course radiotherapy, Consolidation chemotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Shenzhen People's Hospital
Locally Advanced Nasopharyngeal Carcinoma
Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma
This trial is a multi-center phase III clinical trial. The purpose of this trial is to explore whether 2 cycles induction chemotherapy combined with concurrent chemoradiotherapy is not inferior to 3 cycles induction chemotherapy…
- Trial name
- NCT05860868
- Testing
- 2 cycles induction chemotherapy, 3 cycles induction chemotherapy
- Where
- China
- Volunteers
- 474 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
This 3 arm study will assess the tolerability, safety and efficacy of 3 neoadjuvant treatment regimens in participants with locally advanced, inflammatory or early stage human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00976989
- Testing
- Pertuzumab, Trastuzumab, FEC
- Where
- 55 sites in Bosnia and Herzegovina, Brazil and 18 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Malignant Biliary Tract Tumors
A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic Arterial Infusion Chemotherapy (HAIC) With Capecitabine as Adjuvant Therapy After Radical Surgery for Malignant Biliary Tract Tumors
3. Study Design 3.1.1 Study Site and Overall Population Overview This study is a prospective, open-label, randomized controlled clinical trial designed to observe and evaluate the efficacy and safety of hepatic arterial infusion…
- Trial name
- NCT07790445
- Testing
- Oxaliplatin + 5-Fluorouracil/Leucovorin, Capecitabine
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Zhai Wenlong
Pancreatic Cancer
Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy
This randomized trial examines the effectiveness of chemoradiotherapy compared to chemotherapy alone after induction chemotherapy with 3 cycles of gemcitabine or 6 cycles of FOLFIRINOX in patients with locally advanced, non…
- Trial name
- CONKO-007 (NCT01827553)
- Testing
- Induction chemotherapy with gemcitabine or FOLFIRINOX, Radiotherapy, 28 x 1.8 Gy, Chemotherapy, gemcitabine
- Where
- 23 sites in Germany
- Volunteers
- 830 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Metastatic Colorectal Cancer
Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels
In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death risk and strategy stratification are lacking.
- Trial name
- CLavSyn (NCT03117972)
- Testing
- FOLFOXIRI, FOLFOX, FOLFIRI
- Where
- 10 sites in France
- Volunteers
- 54 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Advanced Gastric Cancer
FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer
The prognosis of advanced gastric cancer and adenocarcinoma of the gastro-esophageal (GE) junction is poor. Even with modern chemotherapy the median survival ranges around 8-10 months.
- Trial name
- PaFLO (NCT01503372)
- Testing
- Pazopanib, 5-FU, Oxaliplatin, Leukovorin (FLO)
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Charite University, Berlin, Germany
Adenocarcinoma - GEJ, Adenocarcinoma of the Stomach
A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric
This is a single-arm, open-label, clinical study to evaluate the safety of HER2 tumor vaccine injection alone/in combination with standard of care chemotherapy in patients with HER2/neu overexpressing gastric or gastroesophageal…
- Trial name
- NCT05315830
- Testing
- HER2 Tumor Vaccine, HER2 Tumor Vaccine+ Standard of Care chemotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Advanced Solid Tumor
A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
A multicentre, 2-part study to assess the safety and tolerability of once daily oral doses of AZD2171 when administered with various anticancer regimens (part A) and to confirm the tolerability of its combination with FOLFOX…
- Trial name
- NCT00502567
- Testing
- AZD2171, FOLFOX, Pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.